Surrogacy of one-year survival for overall survival in advanced hepatocellular carcinoma.

ABSTRACT:

Background

The increasing number of sequential treatments complicates the evaluation of overall survival (OS) in clinical trials for hepatocellular carcinoma (HCC), therefore, reliable surrogate endpoints (SEs) are required. This study aimed to evaluate the surrogacy of progression-free survival (PFS) and one-year (1-yr) milestone survival for OS in HCC trials.

Methods

We systematically searched databases for randomized clinical trials that evaluated systemic treatments for advanced HCC. Individual patient data were reconstructed to calculate the 1-yr survival rate. We adopted a two-stage meta-analytic validation model to evaluate the correlation between SEs and OS, and the correlation between treatment effects on SEs and OS. The hazard ratio (HR) was calculated to assess th

SUBMITTER: Jin Y 

PROVIDER: S-EPMC10893652 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature